TScan Therapeutics generated modest collaboration revenue in the fourth quarter driven by its Amgen agreement while significantly narrowing its net loss year-over-year due to reduced operating expenses. The company continued advancing its ALLOHA Phase 1 program and strengthened its pipeline with new IND clearances targeting CD45. Cash resources are expected to fund operations into the second half of 2027.
Revenue increased to 2567000 in Q4 2025 driven by collaboration activities with Amgen.
Net loss narrowed to 22977000 compared with 35809000 in the prior-year quarter.
Operating loss was 23858000 reflecting continued investment in clinical development.
Cash and cash equivalents totaled 152406000 at year-end, expected to fund operations into the second half of 2027.
TScan expects existing cash resources to fund operations into the second half of 2027 while advancing its hematologic malignancies pipeline and initiating new clinical trials.
Analyze how earnings announcements historically affect stock price performance